AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16961791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion condition
Number of subjects: 73
Study 15242999 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic electrocautery of the ovaries followed by CC and recombinant FSH (rFSH)
Number of subjects: 168
Study 15242999 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH)
Number of subjects: 168
Study 11049886 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia
Number of subjects: 90
Study 11049886 — intervention group
Group type: COMPARATOR
Intervention: Non-nitrous oxide anesthesia
Number of subjects: 90
Study 8969629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous disodium EDTA (3 g)
Number of subjects: 60
Study 8969629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1534639 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine stored at 4 degrees C
Number of subjects: 0
Study 1534639 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine heated for 1 week at 45 degrees C
Number of subjects: 0
Study 1534639 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine heated for 1 month at 37 degrees C
Number of subjects: 0
Study 3975851 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (doxorubicin, cyclophosphamide, and high-dose methotrexate)
Number of subjects: 37
Study 3975851 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 37
Study 3975851 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (among entire cohort)
Number of subjects: 37
Study 3975851 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (all patients received)
Number of subjects: 37
Study 30865144 — intervention group
Group type: EXPERIMENTAL
Intervention: COPing with and CAring for infants with special needs (COPCA) program
Number of subjects: 0
Study 30865144 — intervention group
Group type: COMPARATOR
Intervention: Another infant physical therapy
Number of subjects: 0
Study 28096005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lullaby group (n=26) listened to male lullaby via headphones for 20 minutes daily over 3 days
Number of subjects: 52
Study 28096005 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=26) received headphones without sound
Number of subjects: 52
Study 25981087 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted and culturally appropriate intervention
Number of subjects: 1416
Study 25981087 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1416
Study 23440076 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Mind cognitive-training program (8 sessions of 1 hour each)
Number of subjects: 200
Study 23440076 — intervention group
Group type: COMPARATOR
Intervention: Usual group activities provided by DECCs
Number of subjects: 200
Study 21252962 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 21252962 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 20
Study 19021727 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills course (test group)
Number of subjects: 26
Study 19021727 — intervention group
Group type: COMPARATOR
Intervention: Problem-based workshops (control group)
Number of subjects: 26
Study 17347071 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 210
Study 17347071 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinfold Thickness
Number of subjects: 210
Study 15586537 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Number of subjects: 0
Study 15586537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15586537 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 0
Study 11506440 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 73
Study 11506440 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (RGP) contact lenses
Number of subjects: 73
Study 11506440 — intervention group
Group type: EXPERIMENTAL
Intervention: All types of lenses
Number of subjects: 73
Study 11506440 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of contact lens wear
Number of subjects: 73
Study 9205924 — intervention group
Group type: COMPARATOR
Intervention: Resorbable barrier alone
Number of subjects: 14
Study 9205924 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable barrier in combination with decalcified freeze-dried bone allograft (DFDBA)
Number of subjects: 14
Study 9205924 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers in both treatment groups
Number of subjects: 14
Study 9205924 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable barrier and DFDBA in non-smokers
Number of subjects: 14
Study 7741850 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage
Number of subjects: 87
Study 7741850 — intervention group
Group type: COMPARATOR
Intervention: Early elective surgery
Number of subjects: 87
Study 3111785 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 20 mcg/day IUD (LNg20)
Number of subjects: 2244
Study 3111785 — intervention group
Group type: COMPARATOR
Intervention: Copper T IUD (TCu 380Ag)
Number of subjects: 2244
Study 29563078 — intervention group
Group type: EXPERIMENTAL
Intervention: Overcome Social Anxiety (Web-based CBT intervention)
Number of subjects: 0
Study 29563078 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 0
Study 26149244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg/day, with dose modifications allowed)
Number of subjects: 289
Study 25634905 — intervention group
Group type: EXPERIMENTAL
Intervention: O-SES (sirolimus-eluting stent with biodegradable polymer)
Number of subjects: 452
Study 25634905 — intervention group
Group type: COMPARATOR
Intervention: X-EES (everolimus-eluting stent with durable polymer)
Number of subjects: 452
Study 25634905 — intervention group
Group type: EXPERIMENTAL
Intervention: O-SES
Number of subjects: 452
Study 25634905 — intervention group
Group type: COMPARATOR
Intervention: X-EES
Number of subjects: 452
Study 25634905 — intervention group
Group type: EXPERIMENTAL
Intervention: O-SES (subgroup with optical coherence tomography)
Number of subjects: 452
Study 25634905 — intervention group
Group type: COMPARATOR
Intervention: X-EES (subgroup with optical coherence tomography)
Number of subjects: 452
Study 25634905 — intervention group
Group type: EXPERIMENTAL
Intervention: O-SES (subgroup with intravascular ultrasound)
Number of subjects: 452
Study 25634905 — intervention group
Group type: COMPARATOR
Intervention: X-EES (subgroup with intravascular ultrasound)
Number of subjects: 452
Study 24185158 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to increase medication adherence
Number of subjects: 0
Study 21160310 — intervention group
Group type: EXPERIMENTAL
Intervention: No rectopexy
Number of subjects: 252
Study 21160310 — intervention group
Group type: COMPARATOR
Intervention: Rectopexy
Number of subjects: 252
Study 19014153 — intervention group
Group type: COMPARATOR
Intervention: Flap elevation (control group)
Number of subjects: 20
Study 19014153 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless procedure (test group)
Number of subjects: 20
Study 16669842 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 0
Study 16669842 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study 16669842 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of the renin‐angiotensin system
Number of subjects: 0
Study 14700452 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended-release (XR)
Number of subjects: 0
Study 14700452 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release (SR)
Number of subjects: 0
Study 14700452 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled-release (CR)
Number of subjects: 0
Study 14700452 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release formulations
Number of subjects: 0
Study 11202895 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% chlorhexidine gel
Number of subjects: 93
Study 11202895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledermix
Number of subjects: 93
Study 11202895 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide and water
Number of subjects: 93
Study 11202895 — intervention group
Group type: EXPERIMENTAL
Intervention: No medication
Number of subjects: 93
Study 9389098 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 48
Study 9389098 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion
Number of subjects: 48
Study 9389098 — intervention group
Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 48
Study 9389098 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture vs Moxibustion
Number of subjects: 48
Study 1483292 — intervention group
Group type: COMPARATOR
Intervention: Nafarelin and placebo
Number of subjects: 94
Study 1483292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin and norethisterone 0.7 mg
Number of subjects: 94
Study 1483292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin and norethisterone 1.4 mg
Number of subjects: 94
Study 1483292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin and norethisterone 2.45 mg
Number of subjects: 94
Study 1483292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin with or without norethisterone
Number of subjects: 94
Study 2996342 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus hydrochlorothiazide
Number of subjects: 75
Study 2996342 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (hydrochlorothiazide, timolol, and hydralazine)
Number of subjects: 75
Study 29631914 — intervention group
Group type: EXPERIMENTAL
Intervention: hTERT mRNA determination in urine
Number of subjects: 91
Study 29631914 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 91
Study 29631914 — intervention group
Group type: COMPARATOR
Intervention: NMP22
Number of subjects: 91
Study 27053765 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 155
Study 24990004 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in providing MS care
Number of subjects: 221
Study 22247480 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (3 ng/kg per minute for 1 hour) in patients with POTS
Number of subjects: 15
Study 22247480 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline baroreflex sensitivity in patients with POTS
Number of subjects: 15
Study 20193079 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK256066 87.5 mcg once per day
Number of subjects: 24
Study 20193079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18095949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 10328
Study 18095949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10328
Study 15854871 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention designed to decrease endorsement of the thin-ideal
Number of subjects: 217
Study 15854871 — intervention group
Group type: COMPARATOR
Intervention: Underweight communicator
Number of subjects: 217
Study 15854871 — intervention group
Group type: COMPARATOR
Intervention: Average weight communicator
Number of subjects: 217
Study 15854871 — intervention group
Group type: COMPARATOR
Intervention: Overweight communicator
Number of subjects: 217
Study 12823383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle and behavioural interventions (e.g., education about the prostate and bladder, avoiding caffeine, urethral milking, reassurance about prostate cancer)
Number of subjects: 236
Study 12823383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle and behavioural interventions
Number of subjects: 236
Study 11324900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1 mg per day
Number of subjects: 20
Study 11324900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9168853 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskhaler inhaler
Number of subjects: 274
Study 8467027 — intervention group
Group type: EXPERIMENTAL
Intervention: endotracheally administered tobramycin
Number of subjects: 69
Study 8467027 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 69
Study 2870533 — intervention group
Group type: EXPERIMENTAL
Intervention: dihomo‐gammalinolenic acid (DHLA) with depot neuroleptic medication
Number of subjects: 21
Study 2870533 — intervention group
Group type: COMPARATOR
Intervention: placebo depot medication and DHLA capsules
Number of subjects: 21
Study 2870533 — intervention group
Group type: COMPARATOR
Intervention: placebo depot medication and placebo capsules
Number of subjects: 21
Study 28813613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerogen® Solo (Solo) vibrating mesh nebulizer
Number of subjects: 60
Study 28813613 — intervention group
Group type: COMPARATOR
Intervention: Wright jet nebulizer
Number of subjects: 60
Study 27358262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 2.4 mg/ml plus fentanyl 25 µg/ml (NF group)
Number of subjects: 71
Study 27358262 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 25 µg/ml (SF group)
Number of subjects: 71
Study 25063992 — intervention group
Group type: COMPARATOR
Intervention: Feedback on screening outcome and a client information leaflet (Control)
Number of subjects: 0
Study 25063992 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 min of structured brief advice
Number of subjects: 0
Study 25063992 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min of brief lifestyle counselling
Number of subjects: 0
Study 23078878 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated inactivated chimeric PCV1-2 vaccine (Fostera™ PCV; Pfizer Animal Health), administered as a 2.0 ml dose at 21 days of age.
Number of subjects: 40
Study 23078878 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated control group (T03 and T04).
Number of subjects: 40
Study 20515207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral guided self-help (CBT-GSH) delivered in 8 sessions over 12 weeks by master's-level interventionists
Number of subjects: 123
Study 20515207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral guided self-help (CBT-GSH)
Number of subjects: 123
Study 20515207 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 123
Study 18669816 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous etanercept (25 mg) twice weekly
Number of subjects: 88
Study 18669816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 16433194 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg i.v. once daily for 1-4 days followed by azithromycin 500 mg orally once daily for 3 days
Number of subjects: 180
Study 16433194 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime 1.5 g i.v. three times daily for 1-4 days followed by cefuroxime axetil 500 mg orally twice daily for 7 days
Number of subjects: 180
Study 16433194 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 180
Study 16433194 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 180
Study 12939210 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty (n=149)
Number of subjects: 300
Study 12939210 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (n=151)
Number of subjects: 300
Study 12092741 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxifiban (0.75-1.5 mg; n = 20)
Number of subjects: 52
Study 12092741 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxifiban (0.75-1.0 mg; n = 8)
Number of subjects: 52
Study 12092741 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxifiban (0.5-0.75 mg; n = 8)
Number of subjects: 52
Study 12092741 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxifiban (1.5 or 1.0 mg loading dose with or without 325 mg aspirin; n = 16)
Number of subjects: 52
Study 12092741 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxifiban (1.25-1.5 mg)
Number of subjects: 52
Study 12092741 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 52
Study 12092741 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxifiban (various doses)
Number of subjects: 52
Study 12092741 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxifiban with aspirin pretreatment
Number of subjects: 52
Study 10449977 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition with an enteral formula enriched with arginine, omega‐3 fatty acids, and RNA (IEN group; n = 33)
Number of subjects: 100
Study 10449977 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard enteral formula (SEN; n = 35)
Number of subjects: 100
Study 10449977 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN; n = 32)
Number of subjects: 100
Study 10449977 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition (IEN)
Number of subjects: 100
Study 10449977 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard enteral formula (SEN)
Number of subjects: 100
Study 10449977 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 100
Study 7538546 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha
Number of subjects: 152
Study 7538546 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta
Number of subjects: 152
Study 7538546 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-gamma
Number of subjects: 152
Study 7538546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 2254557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 159
Study 2254557 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 159
Study 2254557 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 159
Study 2254557 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase treatment
Number of subjects: 159
Study 7451733 — intervention group
Group type: EXPERIMENTAL
Intervention: Erotic passages depicting women's sexual arousal
Number of subjects: 143
Study 7451733 — intervention group
Group type: COMPARATOR
Intervention: Erotic passages depicting women's disgust
Number of subjects: 143
Study 6436340 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 34
Study 6436340 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 34
Study 28759129 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity intervention (60 minutes daily for two school years)
Number of subjects: 256
Study 28759129 — intervention group
Group type: COMPARATOR
Intervention: Control group (curriculum-defined physical education, 45 minutes twice a week)
Number of subjects: 256
Study 27919261 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent audit and feedback intervention
Number of subjects: 72
Study 24504128 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based vision restoration training for glaucoma (n=15)
Number of subjects: 30
Study 24504128 — intervention group
Group type: COMPARATOR
Intervention: Visual discrimination placebo training (n=15)
Number of subjects: 30
Study 23013506 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐mL glass tubes
Number of subjects: 20
Study 23013506 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐mL plastic tubes
Number of subjects: 20
Study 23013506 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐mL plastic tubes
Number of subjects: 20
Study 23013506 — intervention group
Group type: COMPARATOR
Intervention: 4‐mL plastic tubes
Number of subjects: 20
Study 23013506 — intervention group
Group type: COMPARATOR
Intervention: 6‐mL plastic tubes
Number of subjects: 20
Study 23013506 — intervention group
Group type: COMPARATOR
Intervention: 10‐mL glass tubes
Number of subjects: 20
Study 23013506 — intervention group
Group type: COMPARATOR
Intervention: 10‐mL plastic tubes
Number of subjects: 20
Study 20519876 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost
Number of subjects: 1391
Study 20519876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bosentan
Number of subjects: 1391
Study 20519876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 1391
Study 20519876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1391
Study 17118684 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily
Number of subjects: 107
Study 17118684 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg plus fluticasone 250 microg twice daily
Number of subjects: 107
Study 15660766 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 500 mg/day
Number of subjects: 351
Study 15660766 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 300 mg/day
Number of subjects: 351
Study 15660766 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 100 mg/day
Number of subjects: 351
Study 15660766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 14636500 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' perception of harmful alcohol consumption limits
Number of subjects: 351
Study 14636500 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual alcohol consumption as recorded in medical records
Number of subjects: 351
Study 14636500 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of perceived harmful limits vs actual consumption
Number of subjects: 351
Study 11004033 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-microg oral clonidine premedication (n = 18)
Number of subjects: 36
Study 11004033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 36
Study 8839320 — intervention group
Group type: EXPERIMENTAL
Intervention: Believers
Number of subjects: 42
Study 8839320 — intervention group
Group type: COMPARATOR
Intervention: Skeptics
Number of subjects: 42
Study 1428380 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g L-Tryptophan (L-TRY) supplementation
Number of subjects: 49